Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based life sciences company Entelos has announced a collaboration with big pharma firm Novartis to conduct research in multiple disease areas.
Subscribe to our email newsletter
Under the terms of the agreement, Novartis will provide R&D funding and Entelos will conduct biosimulation research using its PhysioLab platforms, which predict the effects of drugs using ‘virtual patients’. This unique approach will be used by Novartis to support target evaluation, compound optimization, and phase III clinical trial design.
The Entelos technology will be used to support Novartis development sites and will contribute information to support the company’s drug development process from target evaluation to clinical trial design.
“Entelos is very excited to begin working with Novartis, a world leader in the development of innovation-driven prescription medicines,” stated James Karis, president and CEO of Entelos. “The pharmaceutical industry is realizing the benefits of testing targets and drugs in silico before conducting expensive clinical trials.”
Financial terms of the collaboration agreement were not disclosed.